



## Mirum Pharmaceuticals to Present at Cantor 2019 Global Healthcare Conference

September 26, 2019

FOSTER CITY, Calif.--(BUSINESS WIRE)--Sep. 26, 2019-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will present an overview of the company at the Cantor 2019 Global Healthcare Conference.

- Location: New York, NY
- Presentation date: Friday October 4, 2019
- Presentation time: 10:40 a.m. ET

A live audio webcast and archive of the presentation will be available at <http://ir.mirumpharma.com>

### About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). For more information, visit [MirumPharma.com](http://MirumPharma.com). Follow Mirum on [Twitter](#), [Facebook](#) and [LinkedIn](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190926005227/en/>

Source: Mirum Pharmaceuticals, Inc.

### Media Contact:

Heidi Chokeir, Ph.D.  
Canale Communications  
619-203-5391  
[heidi@canalecomm.com](mailto:heidi@canalecomm.com)

### Investor Contact:

Ian Clements, Ph.D.  
650-667-4085  
[ir@mirumpharma.com](mailto:ir@mirumpharma.com)